Takeda Pharmaceutical Co. said at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14, 2026, that it is shifting from deep pipeline investment toward product launches, with a U.S. launch of ORZEYFUL planned later this year and a March 13, 2027 PDUFA date for zasocitinib. Incoming CEO Julie Kim is expected to outline strategy at an all-day December 11 capital markets day in Tokyo. Andy Plump, head of research and development, said he is retiring after 12 years in the role and more than 15 years at Takeda, leaving an 8- to 9-month transition window. Plump said he was confident in the company's future under Kim, Rhonda Pacheco and the team.
Takeda shares were recently at $18.63, up about 2% from the previous close of $18.26, with a 52-week range of $12.99 to $18.90 and a dividend yield of 2.64%. The company has paid dividends for 35 consecutive years and increased them for four straight years. InvestingPro rated its financial health good, citing strong free cash flow despite a lack of profitability over the last 12 months due to heavy pipeline investment.
ORZEYFUL, an orexin agonist for narcolepsy type 1, a condition in which orexin neurons are lost, received FDA approval with a clean label in the first week of August. DEA scheduling is expected in November, using the agency's 90-day window, with a Schedule IV classification anticipated. Rhonda Pacheco, head of Takeda's U.S. business unit, said 80% of patients treated today still have residual symptoms and roughly 50% of narcolepsy type 1 patients remain undiagnosed. The promotion approach will focus on monotherapy and switching from older therapies, including oxybates, rather than add-on use, with twice-daily dosing flexibility.
Zasocitinib is a highly selective TYK2 inhibitor with no JAK activity. One-year safety data from a dedicated study showed no new safety findings. Takeda gave peak sales guidance of $3 billion to $6 billion for psoriasis and psoriatic arthritis, but did not provide peak sales figures for inflammatory bowel disease or ORZEYFUL. IBD data readouts are expected by the end of fiscal 2024, while psoriatic arthritis Phase III data, hidradenitis suppurativa Phase II data and vitiligo Phase II data are expected in 2025. For IBD, dosing starts at the psoriasis dose of 30 mg once daily and escalates to much higher doses. Takeda cited human genetics showing that about 1 in 500 people of Caucasian descent with 90% reductions in TYK2 activity are largely protected from Crohn's disease.
Other pipeline updates included MIMRYLO, which was launched around September 2026. TAK-360, or balumorexton, has Phase II data expected later in 2024 for idiopathic hypersomnia and narcolepsy type 2. TAK-495 is finishing Phase I, with Phase II data expected in 2025. A third orexin molecule is expected to enter the clinic within the next couple of months. Elritercept Phase II data in acute ischemic stroke are expected in 2025, with broader launches expected in 2026 and 2027. Mezagitamab and fazirsiran launches are also expected in 2026 and 2027. Innovent is a partner for programs in China, including TAK-928 and TAK-921.
Takeda described its strategy in two phases. Horizon One involves deep pipeline investment, launch support and lower overall growth. Horizon Two is intended to deliver more meaningful accelerated growth, potentially moving faster than a traditional five-year timeline. Pacheco said Horizon One is focused on execution, describing it as a period of head-down work that Takeda will emphasize publicly.
